$5M Lilly Milestone and 500%+ FY2027 Revenue Growth Guidance
VIVS has more than doubled off its 52-week low of $0.78.
Summary
VivoSim received a $5M milestone payment from Eli Lilly for dosing the first patient in a Phase 2 study of a previously sold IBD drug. The company remains eligible for up to $45M in additional milestones. Management guided for over 500% revenue growth in FY2027, citing traction with its NAMs models, and separately stated that FY27 revenue is expected to grow significantly. This follows a 10-K filed yesterday that disclosed a going concern warning and a stockholders' deficit, making the cash infusion and growth outlook critical. The milestone validates the platform's downstream potential, while the guidance signals a sharp ramp in contract research services. Execution on the revenue target will be the key metric to watch.
At the time of this announcement, VIVS was trading at $2.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.78 to $5.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.